Hydroxychloroquine for Prostate Cancer

This trial tests hydroxychloroquine, a drug typically used for malaria, to determine its potential in treating prostate cancer. The primary goal is to understand how this drug affects cancer cells and assess its safety for patients planning prostate surgery. Participants must have prostate cancer that can be surgically removed and must not have undergone previous treatments like radiation or chemotherapy. The trial involves taking either the actual drug or a placebo (a harmless pill resembling the drug) before surgery. As an Early Phase 1 trial, this research aims to understand how hydroxychloroquine works in people, offering participants a chance to contribute to groundbreaking cancer treatment research.

The trial requires that you stop taking certain medications, such as disease-modifying anti-rheumatic drugs (DMARDs) and any drugs that might affect autophagy, like calcitriol and chloroquine. If you are taking medications that can cause a heart rhythm problem called torsades de pointes, you must stop them for a period longer than six times their half-life before joining the study.

Research has shown that hydroxychloroquine (HCQ) is generally well-tolerated by patients in early studies. It has been tested in lab models and trials to slow tumor growth, showing potential as a cancer treatment. This drug blocks a process called autophagy, which cancer cells use to survive.

Previous studies on hydroxychloroquine have not identified major safety issues. However, like any medication, it can cause side effects, such as mild nausea or dizziness. This trial is in its early stages, so scientists are still gathering detailed safety information.

Most treatments for prostate cancer currently involve hormone therapy, chemotherapy, or radiation. But hydroxychloroquine works differently, targeting cancer cells' survival mechanisms by interfering with autophagy, a process cells use to break down and recycle components. Researchers are excited because hydroxychloroquine could potentially enhance the effectiveness of existing therapies by making cancer cells more susceptible to treatment. Plus, it's an oral medication, which might offer a more convenient option for patients compared to some traditional therapies.

Research suggests that hydroxychloroquine (HCQ), which participants in this trial may receive, might help treat prostate cancer. HCQ has been found to increase the production of a protein called PAR-4, which can slow tumor growth. Studies also indicate that HCQ affects certain processes involved in cancer development, offering a hopeful approach to managing the disease. Additionally, HCQ blocks a process called autophagy, which cancer cells use to survive, making it a potential anticancer treatment. Overall, early results are promising, but more research is needed to confirm its effectiveness specifically for prostate cancer.¹²⁴⁵⁶